Fulgent Genetics, Inc. — Form 8-K
Filed November 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On November 16, 2026, Fulgent Genetics executed a material definitive agreement (Item 1.01) and created a direct financial obligation or off-balance sheet arrangement (Item 2.03). The filing does not disclose the counterparty name, dollar amount, terms, or nature of the obligation in this document summary; full details would appear in exhibits not shown in this index page.
Why this rating
Items 1.01 and 2.03 flags suggest material transaction, but no concrete dollar amounts, counterparty, or terms disclosed in accessible text. Cannot assess magnitude relative to $284M market cap without specifics.
Extracted items
- 1.01 material agreement
- 2.03 material obligation
See more from November 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.